查詢結果分析
相關文獻
- Antimicrobial Susceptibility Testing for Klebsiella Pneumoniae Isolates Resistant to Extended-Spectrum β-Lactam Antibiotics
- Serratia Marcescens Bacteremia: Clinical Features and Antimicrobial Susceptibilities of the Isolates
- 治療耐萬古黴素菌株藥物研究進展
- Capnocytophaga Bacteremia:Clinical Features of Patients and Antimicrobial Susceptibility of Isolates
- 院內感染大腸桿菌菌株及其對抗生素之感受性
- 鏈黴菌Streptomyces Coelicolor之蛋白質體研究
- 黑殭菌抗殺菌劑菌株之篩選
- Action of Antibiotics on Capsular Polysaccharide-Synthesizing Escherichia Coli Infection and Its Exotoxin Challenge in Mice
- A New Antitumor Antibiotic, Chounghwamycin A(1):Taxonomy, Isolation and Characterization
- Comparative Study of the Biotype, Hemolysin-producing Capability and Antibiogram of the Aquatic and the Clinical Strains of Aeromonas hydrophila
頁籤選單縮合
題 名 | Serratia Marcescens Bacteremia: Clinical Features and Antimicrobial Susceptibilities of the Isolates=Serratia Marcescens菌血症: 臨床特色與其菌株之抗生素感受性 |
---|---|
作 者 | 余文良; 林振文; 王德源; | 書刊名 | 微免與感染雜誌 |
卷 期 | 31:3 1998.09[民87.09] |
頁 次 | 頁171-179 |
分類號 | 415.15 |
關鍵詞 | 菌株; 抗生素; Serratia Marcescens菌血症; Antimicrobial susceptibility; Serratia marcescens; Bacteremia; |
語 文 | 英文(English) |
中文摘要 | 本研究為分析1996年7月至1997年6月間,中國醫藥學院附設醫院診斷 S. marcescens 菌血症之 22 位成人病例。所有病人均有嚴重之潛在性疾病,以糖尿病最常 見( 27 %)。82 %病例屬於院內感染。 臨床症候群包括原發性菌血症( 68 %),肺炎 ( 14 %), 泌尿道感染( 9 %), 化膿性血栓靜脈炎( 5 %),及手術傷口感染( 5 %)。 S. marcescens 感染之進入口有 64 %仍不明確。12 名病人於菌血症發生時有放置 中央靜脈導管,僅一名病例確認為中央靜脈導管相關之感染。 23 %有多發性菌血症。全部 病例死亡率為 50 %, 有 32 %死因與 S. marcescens 菌血症相關。 所有菌株對 ampicillin 及 cephalothin 皆具有抗藥性,但均對 imipenem 具感受性。其他抗菌藥物之 有效率分別為 moxalactam ( 95 %), amikacin ( 68 %),ceftazidime ( 55 %) , aztreonam ( 45 %), ceftriaxone ( 32 %), getamicin ( 27 %), cefoperazone ( 18 %),cefotaxime ( 18 %),及 piperacillin ( 9 %)。 測試 各種抗菌藥物之 MICs, 結果顯示 ciprofloxacin ( MIC90: 0.09 μ g ╱ mL )及 imipenem ( MIC90:1.0 μ g ╱ mL )對 S. marcescens 有很好之抗菌效果。 因為多重 抗藥性逐漸增加,適當的抗菌藥物如 moxalactam,imipenem,及 ciprofloxacin 等,在治 療 S. marcescens 感染時,可為優先考慮選擇之藥物。 |
英文摘要 | From July 1996 to June 1997, 22 adult patients with Serratia marcescens bacteremia were retrospectively studied at China Medical College Hospital. All patients had severe underlying disease, most commonly diabetes mellitus. Eighteen (82%) patients had nosocomial infection. Clinical syndromes included primary bacteremia (68%), pneumonia (14%), urinary tract infection (9%), suppurative thrombophlebitis (5%) and surgical wound infection (5%). Twelve patients had central venous catheters in place at the onset of bacteremia, but only one case met the definition of catheter-related infection. In 14 (64%) patients, portal of entry of S. marcescens infection was unknown. Five (23%) patients had concurrent polymicrobial bacteremia. The overall mortality rate was 50% (11/22). Seven (32%) of the 22 patients died of S. marcescens bacteremia. All isolates were resistant to ampicillin and cephalothin and susceptible to imipenem. Ninety-five percent of strains were susceptible to moxalactam, 68% to amikacin, 55% to ceftazidime, 45% to aztreonam, 32% to ceftriaxone, 27% to gentamicin, 18% to cefoperazone and cefotaxime, and 9% to piperacillin. MICs of various antibiotics demonstrated that ciprofloxacin and imipenem had good activities against S. marcescens, with MIC90 of 0.19 μ g/mL and 1.0 μ g/mL, respectively. Due to increasing multidrug resistance, choosing appropriate antimicrobial agents such as moxalactam, imipenem, and ciprofloxacin should be highly recommended for the treatment of S. marcescens infections. |
本系統中英文摘要資訊取自各篇刊載內容。